Expressions and clinical significances of Livin and vascular endothelial growth factor in human pancreatic carcinoma

doi:10.3760/cma.j.issn.1673-422X.2014.09.017

Abstract

Abstract: ObjectiveTo investigate the expressions of Livin and vascular endothelial growth factor (VEGF) in pancreatic carcinoma and their cilinical significances. MethodsThe expressions of Livin and VEGF proteins were tested by immunohistochemistry in 68 cases of pancreatic carcinomas and 44 cases of adjacent paracancerous tissues．ResultsThe positive rates of Livin in pancreatic carcinomas and adjacent paracancerous tissues were 73.5% and 4.5% respectively, and the difference was statistically significant (χ2=48.137, P＜0.001). The positive rates of VEGF in pancreatic carcinomas and adjacent paracancerous tissues were 69.1% and 13.6% respectively, and the difference was statistically significant (χ2=29.147, P＜0.001). The expressions of Livin and VEGF were related with tumor differentiation (χ2=6.061, P=0.014; χ2=6.592, P=0.010), TNM stage (χ2=4.175, P=0.041; χ2=9.992, P=0.002), lymph node metastasis (χ2=11.731, P=0.001; χ2=12.002, P=0.001) and neural invasion (χ2=9.950, P=0.002; χ2=7.433, P=0.006). Significantly positive correlation was found between the expressions of Livin and VEGF by using Spearman correlation analysis (r=0.320, P=0.008). Survival analysis showed that the expressions of Livin and VEGF were independent prognostic factors in pancreatic carcinoma. ConclusionLivin and VEGF involve in the development, migration and metastasis of pancreatic carcinoma. Livin may upregulate the expression of VEGF, which may lead to the angiogenesis and migration in pancreatic carcinoma.

Key words: Pancreatic neoplasms, Gene, Vascular endothelial growth factors, Immunohischemistry

Xue Dong, Zhao Haixia, Chang Gang, Li Xinjun, Li Mengyu, Cheng Piguang, Zhang Chengde, Zhang Tongjun. Expressions and clinical significances of Livin and vascular endothelial growth factor in human pancreatic carcinoma[J]. Journal of International Oncology, 2014, 41(8): 700-703.

References

［1］ Fry LC, Monkemüller K, Malfertheiner P. Molecular markers of pancreatic cancer: development and clinical relevance［J］. Langenbecks Arch Surg, 2008, 393(6): 883-890. ［2］ Guo H, Gao YT, Zhang Q, et al. Expression and clinical significance of livin protein in hepatocellular carcinoma［J］. Dis Markers, 2013, 35(5): 489-496. ［3］ Xue D, Zuo K, Li X, et al. Expression and prognostic significance of Livin, caspase3 and ki67 in the progression of human ampullary carcinoma［J］. Appl Immunohistochem Mol Morphol, 2013, 21(6): 525-531. ［4］张雷. 食管鳞癌组织中诱导型一氧化氮合酶和血管内皮生长因子的表达及意义［J］. 国际肿瘤学杂志, 2012, 39(12): 950-952. ［5］ Park ST, Kim BR, Park SH, et al. Suppression of VEGF expression through interruption of the HIF 1α and Akt signaling cascade modulates the anti angiogenic activity of DAPK in ovarian carcinoma cells［J］. Oncol Rep, 2014, 31(2): 1021-1029. ［6］ Vucic D, Stennicke HR, Pisabrro MT, et al. MLIAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas［J］. Curr Biol, 2000, 10(21): 1359-1366．［7］ Ding ZY, Liu GH, Olsson B, et al. Upregulation of the antiapoptotic factor Livin contributes to cisplatin resistance in colon cancer cells［J］. Tumour Biol, 2013, 34(2): 683-693. ［8］ Xi RC, Sheng YR, Chen WH, et al. Expression of survivin and livin predicts early recurrence in nonmuscle invasive bladder cancer［J］. J Surg Oncol, 2013, 107(5): 550-554. ［9］ Lopes RB, Gangeswaran R, McNeish IA, et al. Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy［J］. Int J Cancer, 2007, 120(11): 2344-2352. ［10］ Xiao X, Yang M, Xiao J, et al. Paris Saponin Ⅱ suppresses the growth of human ovarian cancer xenografts via modulating VEGFmediated angiogenesis and tumor cell migration［J］. Cancer Chemother Pharmacol, 2014, 73(4): 807-818. ［11］ Li R, Luo M, Ren M, et al. Vitronectin regulation of vascular endothelial growth factormediated angiogenesis［J］. J Vasc Res, 2014, 51(2): 110-117. ［12］ Chen L, Ren GS, Li F, et al. Expression of livin and vascular endothelial growth factor in different clinical stages of human esophageal carcinoma［J］. World J Gastroenterol, 2008, 14(37): 5749-5754. ［13］ Qu JM, Ye B, Qiu MK, et al. Knockdown of Livin inhibits growth and invasion of gastric cancer cells through blockade of the MAPK pathway in vitro and in vivo［J］. Int J Oncol, 2014, 44(1): 276-284.

[1]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[2]	Wang Kun, Zhou Zhongxin, Zang Qiwei. Predictive value of serum TGF-β1 and VEGF levels in patients with non-small cell lung cancer after single-port thoracoscopic radical resection [J]. Journal of International Oncology, 2024, 51(4): 198-203.
[3]	Jiang Xi, Wu Yongcun, Liang Yan, Chu Li, Duan Yingxin, Wang Lijun, Huo Junjie. Impact of pembrolizumab combined with chemotherapy on angiogenesis and circulating endothelial cells in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(2): 89-94.
[4]	Liu Xiaodi, Su Jianfei, Zhang Jingxian, Wei Xueqin, Jia Yingjie. Research progress of myeloid-derived suppressor cells in tumor angiogenesis [J]. Journal of International Oncology, 2024, 51(1): 50-54.
[5]	Ye Tongtong, Wu Zeyu, Xi Wenyi, Wang Zhiwei, Jiang Xiaochun, Zhao Chenhui. Role of ABRACL in the occurrence and development of malignant tumors [J]. Journal of International Oncology, 2023, 50(9): 544-547.
[6]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[7]	Zhang Yuan, Bai Zhiyu, Li Qi, Feng Qinmei. Current status of research on exosomes in malignancies [J]. Journal of International Oncology, 2023, 50(8): 484-488.
[8]	Wu Jiali, Zhang Jiahui, Zhang Ping, Xiao Xinyue, Li Rui, Zhang Hongyu. Mechanism of Bcl-2 BH4 selective inhibitor BDA-366 on NK/T cell lymphoma cells [J]. Journal of International Oncology, 2023, 50(7): 413-418.
[9]	Li Bin, Zhang Guifang, Zhou Linjing, Yang Xiaodong, He Qiuli, Jia Sisi, Huang Puchao, Liang Jiaxin. Relationships between PIK3CA gene status and clinical features and prognosis in triple-negative breast cancer [J]. Journal of International Oncology, 2023, 50(5): 263-267.
[10]	Liu Bohan, Huang Junxing. Research progress of solute carriers related genes in malignant tumors [J]. Journal of International Oncology, 2023, 50(5): 280-284.
[11]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng. Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer [J]. Journal of International Oncology, 2023, 50(12): 717-722.
[12]	Deng Lili, Duan Xingyu, Li Baozhong. Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma [J]. Journal of International Oncology, 2023, 50(12): 751-757.
[13]	Chen Zhiming, Chen Junjie, Li Li, Ding Qian, Han Yunan, Zhao Hongyu. Identification of critical radioresistance genes in esophageal squamous cell carcinoma by whole exome sequencing [J]. Journal of International Oncology, 2023, 50(10): 592-599.
[14]	Kui Guoju, Huang Jiangbin, Zhang Wenhua, Yang Limin. Effect of regional lymph node diameter on postoperative recurrence in pancreatic cancer patients [J]. Journal of International Oncology, 2023, 50(10): 608-613.
[15]	Zhang Ziyue, Zheng Sihao, Gao Yanjun, Yao Yi, Song Qibin. CRISPR/Cas9 genome editing technology and its applications in tumor therapy [J]. Journal of International Oncology, 2022, 49(9): 546-549.